$RGT

ROYCE GLOBAL TRUST, INC.

No enriched coverage for $RGT in the last 7 days.

$11K
—
CLARK CHRISTOPHER D
0%
See all $RGT insider activity →

ASX Runners of the Week: Argent, Peregrine, NewPeak Metals & Caspin

The article says volatility returned after Trump declared an Iran ceasefire dead, following Iranian strikes on vessels in the Strait of Hormuz and subsequent US air strikes. It notes Brent crude rose above $80/bbl and junior resources stocks rallied. It highlights ASX-listed Argent BioPharma (RGT) up 206% on a US$5.5m CannEpil licensing deal with Splash, and Peregrine Gold (PGD) up 109% and NewPeak Minerals (NPM) up 107% on early gold discoveries.

RGT sentiment & insider activity

Recent RGT coverage spans financial news, insider activity and market movers.

In the last 30 days, RGT insiders filed 1 SEC Form 4 transaction — 1 purchase ($11K) and no sales. The most active reporter was CLARK CHRISTOPHER D, President, with 1 filing.

What's driving RGT

  • Small insider purchase may signal slight confidence but unlikely to move price.

    SEC EDGAR · Oct 1, 2026

  • The article frames the drop as likely trading/dilution-risk driven rather than a specific clinical or regulatory shock.

    kalkine.com.au · Jul 22, 2026

  • Deal structure removes financing overhang and shifts development/regulatory burden to Splash, supporting a bullish re-rating for RGT.

    theage.com.au · Jul 10, 2026

  • The article highlights Royce Global Trust's recent performance and experienced management, suggesting stability and potential for continued value investing. No immediate market-moving events are reported.

    Benzinga · Nov 24, 2025

  • The news highlights Royce Global Trust's (RGT) stable investment approach and historical performance, with no immediate catalysts for significant price movement.

    Benzinga · Oct 27, 2025

AlphAI scores every news story that mentions RGT with an AI model for sentiment and relevance, and aggregates insider trades from ROYCE GLOBAL TRUST, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RGT

Score
$RGTLow

Argent BioPharma Limited (ASX:RGT) Slides About 7.41% as Clinical-Stage Biotech Risk Returns to Focus

Argent BioPharma (ASX:RGT) shares fell about 7.41% intraday on 22 July 2026, with no single disclosed catalyst for the move. The clinical-stage biotech develops candidates including CannEpil, CimetrA, CogniCann and Irnican. In early July 2026, it licensed global CannEpil rights to Splash Beverage Group for about US$5.5m via convertible-note debt forgiveness and royalties.

$RGTMed

ASX Runners of the Week: Argent, Peregrine, NewPeak Metals & Caspin

The article says volatility returned after Trump declared an Iran ceasefire dead, following Iranian strikes on vessels in the Strait of Hormuz and subsequent US air strikes. It notes Brent crude rose above $80/bbl and junior resources stocks rallied. It highlights ASX-listed Argent BioPharma (RGT) up 206% on a US$5.5m CannEpil licensing deal with Splash, and Peregrine Gold (PGD) up 109% and NewPeak Minerals (NPM) up 107% on early gold discoveries.

Related tickers